Search

Displaying results 4281 - 4290 of 9333 in total
  1. Drug

    Human umbilical cord blood mononuclear cell-conditioned medium

    go.drugbank.com/drugs/DB15724
    Experimental

    Then, the medium is filtered and separated from the HUCBCs. … While some of the positive results are credited to HUCBCs’ differentiation potential, the growth factors and cytokines these cells secrete are also implicated.

  2. Drug

    Sampatrilat

    go.drugbank.com/drugs/DB21283
    Experimental

    Sampatrilat is a small molecule drug. Sampatrilat has a monoisotopic molecular weight of 584.25 Da.

    Categories: Agents Acting on the Renin-Angiotensin System
  3. Drug

    XL019

    go.drugbank.com/drugs/DB05243
    Investigational

    XL019 is a selective inhibitor of the cytoplasmic tyrosine kinase JAK2. An IND for XL019 was filed by Exelixis in May 2007.

  4. Drug

    Lumicitabine

    go.drugbank.com/drugs/DB14808
    Investigational

    Tablet) Compared to Their Respective Current Formulations, and to Assess the Effect of Food on the Pharmacokinetics of the 2 New Concept Formulations). … Lumicitabine is under investigation in clinical trial NCT03010059 (A Study to Assess the Relative Bioavailability of JNJ64041575 Administered as 2 Different New Concept Formulations (Oral Suspension and

  5. Drug

    AP5280

    go.drugbank.com/drugs/DB05112
    Experimental

    AP5280 is a novel N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer-bound platinum (Pt) therapeutic designed to increase the therapeutic index relative to conventional, small-molecule platinum agents.

  6. Drug

    Fasedienol

    go.drugbank.com/drugs/DB04968
    Investigational

    PH94B is being developed by Pherin Pharmaceuticals, Inc. for the treatment of social phobias (generalized anxiety disorder).

  7. Drug

    Metocurine

    go.drugbank.com/drugs/DB01336
    Approved

    Patients on chronic anticonvulsant drugs are relatively resistant to metocurine. [A2393]

  8. Drug

    MK-0354

    go.drugbank.com/drugs/DB05939
    Investigational

    It targets G protein-coupled receptor, or GPCR, that have the potential to regulate plasma lipid profiles, including HDL, or the good cholesterol, similar to the therapeutic action of niacin. … MK-0354, is an orally administered drug candidate under development by Merck for the treatment of atherosclerosis and related disorders.

  9. Drug

    Dexpramipexole

    go.drugbank.com/drugs/DB15130
    Investigational

    From the Onset of the QRS Complex to the End of the T Wave Corrected for Heart Rate)). … Dexpramipexole is under investigation in clinical trial NCT01511029 (Study to Evaluate the QTC Interval in Healthy Volunteers Dosed With Dexpramipexole (QTC = Electrocardiogram (ECG) Interval Measured

  10. Drug

    Indium In-111 imciromab pentetate

    go.drugbank.com/drugs/DB09339
    ApprovedWithdrawn

    Indium In-111 imciromab pentetate is a mouse monoclonal antibody labelled with the radioisotope Indium-111 which was used for cardiac imaging under the trade name Myoscint, but was withdrawn in 1993.